DT03 Rec'd PCT/PT0 22 JUL 2004

Form PTO (REV 5-93		IMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER P32976						
10	TRANSMITTAL LETTER T DESIGNATED / ELECTE CONCERNING A FILING	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/502233						
	IATIONAL APPLICATION NO. EP03/00823	INTERNATIONAL FILING DATE 27/01/2003	PRIORITY DATE CLAIMED 29/01/2002						
TITLE OF INVENTION AMINOPIPERIDINE DERIVATIVES									
APPLICANT(S) FOR DO/EO/US Robert A. DAINES, William H. MILLER, Neil D. PEARSON, Israil PENDRAK and Mark A. SEEFELD									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1 [x]	[x] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2. []									
3. [x]	x] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).								
4. [x]	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.								
5. [x]	x] A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
	a. [] is transmitted herewith (required only if not transmitted by the International Bureau).								
	b. [X] has been transmitted by the International Bureau.c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).								
6. []	A translation of the International Application into English (35 U.S.C. 371(c)(2)).								
7. []	a. [] are transmitted herewith (required only if not transmitted by the International Bureau).								
	b. [] have been transmitted by the International Bureau.c. [] have not been made; however, the time limit for making such amendments has NOT expd. [] have not been made and will not be made.								
8. []	A translation of the amenda	nents to the claims under PCT Articl	le 19 (35 U.S. C. 371(c)(3)).						
9. [x]	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10. []	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
Items 11. to 16. below concern other document(s) or information included:									
		Statement under 37 C.F.R. 1.97 and							
12. []	An assignment document for 3.28 and 3.31 is included.	r recording. A separate cover sheet	in compliance with 37 C.F.R.						
13. [x]	A FIRST preliminary amen	dment.							
14 []		Preliminary Amendment for US of ENT preliminary amendment	originating cases only)						
	A SECOND or SUBSEQUENT preliminary amendment. A substitute specification.								
	A change of power of attorr	ney and/or address letter.							
	An Abstract on a separate s								
18. [X]	Other items or information: Copy of Form PCT/ISA/210 (6 pages).								

Free a new

US APPLICATION NO. (if known see 37 CFR 1.50) INTERNATIONAL APPLICATION NO. PCT/EP03/00823				ATTORNEYS DOCKET NO. P32976	
20. [X] The fo	ollowing fees are submit	CALCULATIONS	PTO USE ONLY		
Basic	c National Fee (37 C.F				
Search Repo	ort has been prepared by	\$920.00			
	l Preliminary Examinat				
but internati	ional Preliminary Exam ional search fee paid to				
Neither Inte	rnational Preliminary E Il search fee (37 CFR 1. Il Preliminary Examinat				
	ns satisfied provisions of				
,	ENTER A	\$920.00			
_	30.00 for furnishing the earliest claimed priorit	\$0.00			
Claims	Number Filed	Number Extra	Rate		
Total claims	13 - 20 =	0	0 x \$18.00	\$0.00	
Independent claims	1-3=	0	0 x \$86.00	\$0.00	
Multiple depend	ent claims (if applicable	\$0.00			
		\$920.00			
	2 for filing by small entitles be filed. (Note 37 (\$			
		\$920.00			
	f \$130.00 for furnishing nths from the earliest cla	\$			
		\$920.00			
				Amount to be refunded	\$
				charged	\$

a. A check in the amount of <u>\$</u> to cover the above fees is enclosed.

b. Please charge my Deposit Account No. <u>19-2570</u> in the amount of <u>\$920.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5629

Facsimile (610) 270-5090

SIGNATURE

Chris P. Miller

NAME

55,852

REGISTRATION NO.

n:\cpm\cases\p32976\national stage transmittal.doc

10/502233 DT03 Rec'd PCT/PTO 22 JUL 2004

PATENT ATTORNEY'S DOCKET NUMBER P32976

TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP03/00823 27/01/2003 29/01/2002

TITLE OF INVENTION
AMINOPIPERIDINE DERIVATIVES

√**₹**°

APPLICANT(S) FOR DO/US
Robert A. DAINES, William H. MILLER, Neil D. PEARSON, Israil PENDRAK and Mark A. SEEFELD

Commissioner for Patents Mail Stop: PCT P.O. Box 1450 Alexandria, VA 22313-1450 ATTENTION: DO/US

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date <u>July 22, 2004</u> in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>EL964436040US</u> addressed to the:

Commissioner for Patents, Mail Stop: PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper)

20462

CUSTOMER NUMBER